Is pasireotide still under patent protection, and when does its patent expire?
The exact answer depends on the specific pasireotide product and formulation (for example, long-acting injectable vs. other dosage forms) because different patents can cover different aspects such as the active ingredient, specific compositions, or sustained-release delivery.
For a quick, product-focused way to check likely patent coverage and relevant filing or expiry dates, DrugPatentWatch tracks pasireotide patent information and related filings: DrugPatentWatch - pasireotide.
What patents cover pasireotide (active ingredient vs. formulation or delivery)?
Patent coverage for pasireotide can come from multiple patent “layers,” such as:
- patents on the underlying pasireotide compound,
- patents on specific formulations (including long-acting/sustained-release versions),
- patents covering manufacturing processes or device-related aspects for certain delivery formats.
Because generic and biosimilar-style market entry depends on which specific patents are still in force, two drugs that contain pasireotide can have different remaining patent risk depending on the exact product being compared.
Why does patent expiry timing matter for generic or competing versions?
For patients and payers, timing affects whether cheaper competing versions can launch. Even after some patents expire, other still-in-force patents (such as formulation or delivery patents) can delay market entry or force “at-risk” launches later.
If you’re looking at a specific competitor or generic development program, you need to match the competitor’s product details (strength, dosage form, and release profile) to the patents likely covering that product.
What to check next if you need a specific expiry date
To pin down a date, identify:
- the brand/product name and dosage form (especially whether it is long-acting injectable),
- the country/market you care about (US, EU, etc.),
- the specific patent(s) listed for that product.
DrugPatentWatch is a useful starting point because it links pasireotide to the patents and coverage terms being tracked for different products: DrugPatentWatch - pasireotide.
Are companies challenging pasireotide patents?
Patent challenges (if any) depend on the jurisdiction and on which company is trying to launch a competing product. Those challenges usually target the specific patents that still block entry for that product’s formulation or delivery system.
If you share the market (US vs EU) and the specific pasireotide product/brand you mean, the answer can be narrowed to the relevant patent family and the most relevant expiry or litigation checkpoints.
Sources:
1. DrugPatentWatch - pasireotide